Active trials


Back to Brain Cancer

 

ACED
CABARET
CATNON
NUTMEG
VERTU

ACED

A Phase II randomised placebo-controlled, double blind, multisite study of Acetazolamide versus placebo for management of cerebral oedema in recurrent and/or progressive High Grade Glioma requiring treatment with Dexamethasone – The ACED trial

Trial Summary:

The purpose of this clinical research study is to determine whether adding acetazolamide to dexamethasone improves patient outcome and lessens corticosteroid side-effects in patients with recurrent or progressive high grade glioma. This study will also describe the possible side effects of both dexamethasone and acetazolamide on your quality of life.

Supported By: Perpetual via CBCF; Cancer Australia
Registration ID:ACTRN12615001072505
Participation:Australia
Australian Lead Group:COGNO, NHMRC CTC
Status:Recruiting
Activation Date:24 June 2016
Chairs:Prof Meera Agar
Contact:aced@ctc.usyd.edu.au

CABARET

A randomised phase II study of carboplatin and bevacizumab in recurrent glioblastoma multiforme

Trial Summary:

The Cabaret study aims to measure the effectiveness of the different treatment regimens in terms of survival and wellbeing forpatients with recurrent glioblastoma multiforme (a type of brain tumour).

Supported By: Roche Products Pty Limited; NHMRC CTC; COGNO
Eligibility:Patients with recurrent grade IV glioma (glioblastoma multiforme) who have had radiotherapy and temozolomide chemotherapy.
Registration ID:ACTRN12610000915055
Participation:Local
Australian Lead Group:COGNO
Status:Closed
Activation Date:5/11/2010
Chairs:Kathryn Field (AU)
Contact:cabaret@ctc.usyd.edu.au

CATNON

Phase III trial of concurrent and adjuvant temozolomide chemotherapy in non-1p/19q-deleted anaplastic glioma

Trial Summary:

Catnon aims to identify the benefits of different treatments for patients towards improving patient care. The main objectives are:

1. To determine whether chemotherapy given in addition to radiotherapy or the addition of chemotherapy after the completion of radiotherapy will improve overall survival and the time until tumour progression;

2. To document the effects of chemotherapy when either given at the same time as radiotherapy or after finishing radiotherapy; and

3. To identify patients most likely to benefit from this specific treatment on the basis of analysis of molecular markers from previously resected tumour specimens, which will ultimately allow the development of new treatments more specific to each patient's tumour characteristics.

Supported By: Merck Sharp and Dohme; EORTC; NHMRC CTC; COGNO
Eligibility:Patients with non-1p/19q-deleted anaplastic glioma
Registration ID:ACTRN12609000485235
Participation:International
Australian Lead Group:COGNO
Status:Closed to recruitment; Patients in follow up
Activation Date:21/06/2010
Chairs:Martin van den Bent (international), Anna Nowak
Contact:catnon@ctc.usyd.edu.au

NUTMEG

Phase II randomised, multisite study of Nivolumab and Temozolomide vs Temozolomide alone in newly diagnosed Elderly patients with Glioblastoma.

Trial Summary:

The aim of the study is to evaluate whether the combination of adjuvant nivolumab with temozolomide improves overall survival outcomes of GBM patients who are 65 years of age or older.

Supported By: NHMRC grant and BMS (Drug supply)
Eligibility:Adults, aged ≥70 years, or aged 65-69 years if long course RT is inappropriate, with newly diagnosed histologically confirmed GBM (WHO grade IV glioma including gliosarcoma) following surgery.
Registration ID:ACTRN12617000267358
Participation:Australia
Status:Open to recruitment
Activation Date:22/02/2018
Chairs:Associate Professor Mustafa Khasraw
Contact:nutmeg@ctc.usyd.edu.au

VERTU

A Randomised Phase II study of veliparib + radiotherapy (RT) with adjuvant temozolomide (TMZ) + veliparib versus standard RT + TMZ followed by TMZ in patients with newly diagnosed glioblastoma (GBM) with unmethylated O (6)-methylguanine-DNA methyltransferase (MGMT)

Trial Summary:

This study aims to develop a new treatment for glioblastoma (GBM), by finding out whether giving veliparib (an oral PARPi inhibitor drug) in combination with radiotherapy and follow up chemotherapy will improve the outcome of patients with unmethylated MGMT glioblastoma (GBM). The study will also find out how long the GBM responds to this treatment, the side effects of the treatment and the effect on quality of life.

Supported By: COGNO; Cure Brain Cancer Foundation; AbbVie; Cancer Council New South Wales (CCNSW)
Registration ID:ACTRN12615000407594
Participation:Australia
Australian Lead Group:COGNO, NHMRC CTC
Status:Recruiting
Activation Date:28/10/2015
Chairs:Dr Mustafa Khasraw
Contact:vertu@ctc.usyd.edu.au

 


Go back to brain cancer main page